SCHEMBL19677983

SCHEMBL19677983

CC(C)(C)OC(=O)NCC(=O)O[C@H]1CCC2C3CCc4cc(O[Si](C)(C)C(C)(C)C)ccc4C3CC[C@@]21C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.59
KMT2A Q03164 6/20 0.59
MEN1 O00255 5/20 0.59
THRB P10828 1/20 0.59
CA2 P00918 3/20 0.56
CYP3A4 P08684 6/20 0.55
TP53 P04637 4/20 0.55
ESR1 P03372 4/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
MAPK1 P28482 3/20 0.55
ALOX15 P16050 3/20 0.55
LMNA P02545 8/20 0.53
PGR P06401 3/20 0.53
ADORA3 P0DMS8 3/20 0.53
AR P10275 3/20 0.53
PTGS1 P23219 2/20 0.53
PDE3A Q14432 2/20 0.53
HIF1A Q16665 1/20 0.53
PDE4A P27815 1/20 0.53
CYP2C19 P33261 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19272460 0.88 MAPT (0.66) MAPTKMT2AMEN1THRBCA2
SCHEMBL19272461 0.88 MAPT (0.66) MAPTKMT2AMEN1THRBCA2
SCHEMBL21388202 0.88 MAPT (0.66) MAPTKMT2AMEN1THRBCA2
SCHEMBL19677972 0.87 MAPT (0.65) MAPTKMT2AMEN1THRBCA2
SCHEMBL19286814 0.87 MAPT (0.73) MAPTKMT2AMEN1THRBCA2
SCHEMBL19286025 0.86 MAPT (0.61) MAPTKMT2AMEN1THRBCA2
SCHEMBL19677984 0.85 CA2 (0.79) MAPTKMT2AMEN1THRBCA2
SCHEMBL19677971 0.84 CA2 (0.69) MAPTKMT2AMEN1THRBCA2
SCHEMBL19286030 0.82 MAPT (0.58) MAPTKMT2AMEN1THRBCA2
SCHEMBL19272470 0.82 MAPT (0.58) MAPTKMT2AMEN1THRBCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3019172-B1 PRO-DRUG FORMING COMPOUNDS EVESTRA INC (US) 2019-09-25 EP disclosed
US-10273263-B2 Pro-drug forming compounds EVESTRA, INC. (US) 2019-04-30 US disclosed
US-20170349624-A1 PRO-DRUG FORMING COMPOUNDS EVESTRA, INC. 2017-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170349624-A1 PRO-DRUG FORMING COMPOUNDS SUCNR1, FURIN, PROKR2 MAPT 3071/4885KMT2A 2831/4885MEN1 637/4885
US-10273263-B2 Pro-drug forming compounds SUCNR1, FURIN, OGFR MAPT 3110/4885KMT2A 2533/4885MEN1 748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.